



ID Week poster #516

Implementation of a probiotic for the primary prevention of hospital-onset *Clostridium difficile* infection

Denver Health Medical Center, Denver, CO

Kati Shihadeh, PharmD; Heather Young, MD; Bryan Knepper, MPH, MS, CIC; Robert Tapia, CPhT; Timothy Jenkins, MD

Office: 790 Delaware St MC 0056
Denver, CO 80204
katherine.shihadeh@dhha.org
Phone: 303-602-6986

Background

- Hospital-onset *Clostridium difficile* infection (HO-CDI) affects over 100,000 patients in the U.S. each year.
- Due to a rising rate of HO-CDI at Denver Health, a multifaceted CDI prevention plan was implemented which included a probiotic intervention. Other components of the CDI prevention plan included electronic hand hygiene monitoring, enhanced environmental cleaning, and prospective review of patients with CDI.

Purpose

- The purpose of this study is to describe the implementation and uptake of the probiotic intervention.

Methods

- Retrospective chart review
- Adult, inpatients who received antibiotics considered high-risk for the development of CDI from March 2017 – March 2018. Table of high-risk antibiotics below.

Cephalosporins (≥3rd generation)	Ceftriaxone	Cefdinir	Ceftazidime	Cefepime	Ceftaroline
B-lactam/β-lactamase inhibitors	Amox/clav	Amp/sulb	Pip/tazo		
Carbapenems	Ertapenem	Imipenem	Meropenem		
Other	Levofloxacin	Ciprofloxacin	Moxifloxacin	Clindamycin	

- In March 2017, a Best Practice Advisory (BPA) was implemented to advise providers to order Bio-K+ (*L. acidophilus*, *L. casei*, and *L. rhamnosus*) when they signed an order for a high-risk antibiotic.
- The BPA was suppressed in patients who were pregnant, immunocompromised, unable to take oral medications, or had active CDI.
- The primary outcome was the proportion of patients for whom the probiotic was prescribed when the BPA fired in the first year.
- Secondary outcomes include CDI rates before and after the intervention and adverse events defined as a positive Lactobacillus culture.

▼ Suggestion (Advisory: 1)

Based on the antibiotic(s) prescribed for this patient, unless a contraindication exists, Denver Health guidelines recommend prescription of Bio-K+ probiotic. This probiotic can prevent antibiotic-associated diarrhea and *Clostridium difficile* infection in patients receiving broad-spectrum antibiotics. Contraindicated in immunosuppressed and pregnant patients.

NOTE: the following patients should NOT receive probiotics

- Immunocompromised patients including patients with neutropenia (ANC < 500), receipt of immunosuppressive therapy within the past 30 days, chronic steroid use equivalent to ≥ prednisone 20 mg daily, HIV with CD4 < 200
- Inability to take enteral medications (ie intractable vomiting, bowel obstruction, NPO)
- Active *Clostridium difficile* infection
- Pregnancy

For more information, please visit the Bio-K+ [guideline](#)

Order Do Not Order Bio-K Plus 50 billion CFU capsule

Acknowledge Reason


Contraindicated Other

Results

- The BPA fired in 3,840 cases, and Bio-K+ was ordered in 94.8% of cases.
- Below are demographics for patients who received a high-risk antibiotic for ≥24 hrs


Demographics	N=2,636 courses of Bio-K+
Male, n (%)	1,517 (58)
Age, median (IQR)	61 (41-66)
Length of stay, median days (IQR)	5 (3-9)
Days of Bio-K+, median (IQR)	3 (2-6)
Courses of high risk antibiotics	
Ceftriaxone	1,185 (45)
Cefepime	516 (20)
Piperacillin/tazobactam	279 (11)
Ampicillin/sulbactam	260 (10)
Clindamycin	250 (9)
Levofloxacin	217 (8)
Other	176 (7)

- The HO-CDI rates for one year pre and post intervention were 0.75 and 0.60 cases per 1000 patient days, respectively (p=0.16).



- During the study period, Lactobacillus was cultured in 11 patients (12 cultures). The proportion of patients who received a course of Bio-K+ and subsequently had a positive culture with Lactobacillus was 0.4%.

Lactobacillus cultures during study period



- After review of the medical record, the 5 positive Lactobacillus cultures from patients receiving the probiotic were all polymicrobial cultures and not thought to be due to the probiotic.

Conclusions

- A probiotic intervention for the prevention of CDI implemented via BPA had excellent provider uptake.
- As part of a multifaceted CDI action plan, a probiotic intervention had a low risk of serious adverse events.

Future direction:

- Compare the incidence of CDI in patients who received the probiotic vs those who received the same high-risk antibiotics without the probiotic
- Perform a cost analysis on the probiotic intervention